Bipolar disorder: Quality of life and the impact of atypical antipsychotics

American Journal of Managed Care

Volumn 11, Issue SUPPL. 9, 2005, Pages

  Vornik, Lana A ^a   Hirschfeld, Robert M A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; ZIPRASIDONE;

ACNE; AKATHISIA; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DIABETES INSIPIDUS; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; EMOTIONAL DISORDER; EXTRAPYRAMIDAL SYMPTOM; FUNCTIONAL ASSESSMENT; HUMAN; JOB PERFORMANCE; LIFESTYLE; MANIA; MOTOR DYSFUNCTION; NAUSEA AND VOMITING; NEUROTOXICITY; OUTCOMES RESEARCH; PARKINSONISM; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT SATISFACTION; POLYDIPSIA; POLYURIA; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOCIAL DISABILITY; SOCIAL INTERACTION; SUICIDE ATTEMPT; SYMPTOM; TARDIVE DYSKINESIA; THYROID DISEASE; TREMOR; WEIGHT GAIN; WELLBEING; WORK DISABILITY;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS; LIFE STYLE; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRES; SICKNESS IMPACT PROFILE;

EID: 27544511360     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Akiskal HS, Bourgeois ML, Angst J, Post R, Moller H, Hirschfeld R. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord 2000;59(suppl 1):S5-S30.
2. Angst J, Gamma A, Benazzi F, Ajdacic V, Eich D, Rossler W. Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J Affect Disord. 2003;73:133-146.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition, revised (DSM-IV). Washington, DC: American Psychiatric Press; 1994.
4. Calabrese JR, Hirschfeld RM, Reed M, et al. Impact of bipolar disorder on a US community sample. J Clin Psychiatry, 2003;64:425-432.
5. Das AK, Olfson M, Gameroff MJ, et al. Screening for bipolar disorder in a primary care practice. JAMA. 2005;293:956-963.
6. Tohen M, Zarate CA Jr, Hennen J, et al. The McLean-Harvard First-Episode Mania study: prediction of recovery and first recurrence. Am J Psychiatry. 2003;160:2099-2107.
7. Namjoshi MA, Buesching DP. A review of the health-related quality of life literature in bipolar disorder. Qual Life Res. 2001;10:105-115.
8. Leidy NK, Palmer C, Murray M, Robb J, Revicki DA. Health-related quality of life assessment in euthymic and depressed patients with bipolar disorder. Psychometric performance of four self-report measures. J Affect Disord. 1998;48:207-214.
9. Goldberg JF, Harrow M, Grossman LS. Course and outcome in bipolar affective disorder: a longitudinal follow-up study. Am J Psychiatry. 1995;152:379-384.
10. Harrow M, Goldberg JF, Grossman LS, Meltzer HY. Outcome in manic disorders. A naturalistic follow-up study. Arch Gen Psychiatry. 1990;47:665-671.
11. Coryell W, Scheftner W, Keller M, Endicott J, Maser J, Klerman GL. The enduring psychosocial consequences of mania and depression. Am J Psychiatry. 1993;150:720-727.
12. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530-537.
13. Hirschfeld RM, Calabrese JR, Frye MA, Wagner KD, Reed M. Burden of manic versus depressive symptoms in patients with bipolar disorder. Poster presented at: Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, Calif. [NR388].
14. Hirschfeld RM, Calabrese JR, Frye MA, Wagner KD, Reed M. Impact of bipolar depression compared with unipolar depression. Poster presented at: Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, Calif. [NR389].
15. Baldessarini RJ. Treatment research in bipolar disorder: issues and recommendations. CNS Drugs. 2002;16:721-729.
16. Ritsner M, Gibel A, Perelroyzen G, Kurs R, Jabarin M, Ratner Y. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol. 2004;24:582-591.
17. Atkinson M, Zibin S, Chuang H. Characterizing quality of life among patients with chronic mental illness: a critical examination of the self-report methodology. Am J Psychiatry. 1997;154:99-105.
18. Vojta C, Kinosian B, Click H, Altshuler L, Bauer MS. Self-reported quality of life across mood states in bipolar disorder. Compr Psychiatry. 2001;42;190-195.
19. Wirshing WC. Movement disorders associated with neuroleptic treatment. J Clin Psychiatry. 2001;62(suppl 21):15-18.
20. Naber D, Karow A. Good tolerability equals good results: the patient's perspective. Eur Neuropsychopharmacol. 2001;11(suppl 4):S391-S396.
21. Hirschfeld RMA. The efficacy of atypical antipsychotics in bipolar disorders. J Clin Psychiatry. 2003;64 (suppl 8):15-21.
22. Vieta E, Goikolea JM. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord 2005;7(suppl 4):21-33.
23. Namjoshi MA, Rajamannar G, Jacobs T, et al. Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial. J Affect Disord. 2002;69:109-118.
24. Namjoshi MA, Risser R, Shi L, Tohen M, Breier A. Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid. J Affect Disord. 2004;81:223-229.
25. Hirschfeld RMA, Eerdekens M, Kalali AH, et al. An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder. Int Clin Psychopharmacol. In press.
26. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005;66:111-121.
27. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K; Ziprasidone in Mania Study Group. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160:741-748.